Lilly bypasses insurers with employer GLP-1 program

Good morning, healthcare professional.

Eli Lilly is rewriting the rules of drug distribution with a direct-to-employer program for obesity medications, while Moderna closes a multibillion-dollar chapter in COVID vaccine patent litigation. Meanwhile, the FDA is intensifying its regulatory enforcement against telehealth companies selling compounded GLP-1 drugs, and early assessments of the Trump administration's drug pricing initiative reveal limited impact.

These developments signal major shifts in how pharmaceutical companies reach patients, how intellectual property disputes shape the industry's future, and how regulatory agencies balance innovation with safety. From business model innovation to patent settlements and enforcement actions, today's news reflects an industry navigating complex challenges around access, pricing, and compliance.

In today's healthcare digest:

• Eli Lilly launches direct-to-employer platform for obesity drugs
• Moderna settles COVID vaccine patent dispute for $2.25 billion
• FDA issues 30 warning letters to GLP-1 compounders
• TrumpRx program shows limited results one month in

Lilly Bypasses Traditional Insurance with Employer-Direct Obesity Drug Program

Eli Lilly has launched a direct-to-employer platform allowing companies to subsidize Zepbound for employees outside traditional insurance channels. The move represents a significant departure from conventional pharmaceutical distribution models.

Unpacked:

• Employers can now purchase Lilly's obesity medication directly, bypassing pharmacy benefit managers and insurance companies entirely.
• The program addresses widespread employer frustration with limited GLP-1 coverage, as many plans exclude obesity drugs due to cost concerns.
• This distribution strategy could reshape pharmaceutical access if successful, potentially influencing how other high-cost medications reach patients.

Moderna Pays $2.25 Billion to Settle COVID Vaccine Patent Litigation

Moderna agreed to pay up to $2.25 billion to settle patent disputes with Genevant and Arbutus over mRNA vaccine technology. The settlement resolves years of litigation surrounding the company's COVID-19 vaccine.

Unpacked:

• The settlement includes $950 million upfront, with additional payments contingent on future vaccine sales and licensing agreements.
• The dispute centered on lipid nanoparticle delivery technology critical to mRNA vaccine effectiveness and stability.
• Resolving these patent claims clears a path for Moderna to develop future mRNA therapeutics without ongoing litigation risk.

FDA Escalates Crackdown on Compounded GLP-1 Drugs with 30 Warning Letters

The FDA issued 30 warning letters to telehealth companies and compounding pharmacies selling versions of popular weight loss medications. The enforcement action targets firms the agency believes are violating compounding regulations.

Unpacked:

• The warning letters focus on companies marketing compounded semaglutide and tirzepatide despite official shortage declarations ending.
• FDA regulations permit compounding only during drug shortages, and the agency has determined GLP-1 supply has stabilized.
• The crackdown affects a growing telehealth sector that emerged to fill gaps when branded obesity drugs were unavailable.

TrumpRx Drug Pricing Program Shows Limited Impact After First Month

One month after launch, the TrumpRx initiative has delivered fewer drugs and smaller discounts than initially promised. The program aimed to provide Americans with dramatically lower prescription drug prices.

Unpacked:

• The platform currently offers a limited formulary with discounts that vary widely across medications and don't consistently beat existing options.
• Implementation challenges and pharmaceutical company participation issues have slowed the program's expansion beyond initial projections.
• Patient advocacy groups question whether the initiative will achieve meaningful savings for Americans struggling with medication costs.

The Shortlist

• Glenmark received FDA approval for the first true generic version of GSK's asthma inhaler Flovent, potentially improving access to this essential medication.

• Science Corp raised $230 million to bring its retinal implant technology to American patients awaiting FDA approval.

• Galderma doubled its peak sales projection for Nemluvio to over $4 billion following a strong first year in the atopic dermatitis market.

• Atavistik Bio secured $160 million in Series B funding to advance treatments for rare blood disorders.

• Blackstone invested $400 million in Teva and Sanofi's gut disease drug development program, backing duvakitug's clinical advancement.